UY30915A1 - Método de tratamiento de canceres - Google Patents

Método de tratamiento de canceres

Info

Publication number
UY30915A1
UY30915A1 UY30915A UY30915A UY30915A1 UY 30915 A1 UY30915 A1 UY 30915A1 UY 30915 A UY30915 A UY 30915A UY 30915 A UY30915 A UY 30915A UY 30915 A1 UY30915 A1 UY 30915A1
Authority
UY
Uruguay
Prior art keywords
treatment method
cancer treatment
mammal
syndromes
invented
Prior art date
Application number
UY30915A
Other languages
English (en)
Inventor
Connie L Erickson-Miller
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690807&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY30915(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of UY30915A1 publication Critical patent/UY30915A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

Se inventa un método para tratar cánceres y síndromes precancerosos en un mamífero, incluyendo un ser humano, que lo necesita, que comprende la administracion de una cantidad terapéuticamente eficaz de un agonista no peptídico del receptor de TPO a dicho mamífero.
UY30915A 2007-02-16 2008-02-13 Método de tratamiento de canceres UY30915A1 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US89023607P 2007-02-16 2007-02-16
US89255207P 2007-03-02 2007-03-02
US90820507P 2007-03-27 2007-03-27
US94934707P 2007-07-12 2007-07-12
US95228907P 2007-07-27 2007-07-27
US96919207P 2007-08-31 2007-08-31
US97721607P 2007-10-03 2007-10-03

Publications (1)

Publication Number Publication Date
UY30915A1 true UY30915A1 (es) 2008-09-02

Family

ID=39690807

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30915A UY30915A1 (es) 2007-02-16 2008-02-13 Método de tratamiento de canceres

Country Status (27)

Country Link
US (2) US20100075928A1 (es)
EP (1) EP2124547B1 (es)
JP (1) JP5511391B2 (es)
KR (1) KR101447763B1 (es)
CN (1) CN101662937B (es)
AR (1) AR065348A1 (es)
AU (1) AU2008216106B9 (es)
BR (1) BRPI0807940B8 (es)
CA (1) CA2678358C (es)
CR (1) CR10997A (es)
DK (1) DK2124547T3 (es)
EA (1) EA017715B1 (es)
ES (1) ES2675070T3 (es)
HU (1) HUE038563T2 (es)
IL (2) IL200319A (es)
MA (1) MA31202B1 (es)
MX (1) MX2009008822A (es)
NZ (1) NZ579068A (es)
PE (1) PE20081784A1 (es)
PL (1) PL2124547T3 (es)
PT (1) PT2124547T (es)
SI (1) SI2124547T1 (es)
TR (1) TR201809010T4 (es)
TW (1) TW200906393A (es)
UY (1) UY30915A1 (es)
WO (1) WO2008101141A2 (es)
ZA (1) ZA200905532B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110129550A1 (en) * 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
KR101530402B1 (ko) * 2007-10-09 2015-06-19 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 급성 인간 골수성 백혈병 세포를 죽이는 트롬보포이에틴 수용체 효능제 (ｔｐｏｒａ)
PL3127427T3 (pl) 2009-05-29 2020-06-15 Novartis Ag Sposoby podawania związków agonistów trombopoetyny
US20130171141A1 (en) * 2010-09-01 2013-07-04 Novartis Ag Combination of hdac inhibitors with thrombocytopenia drugs
WO2014150252A1 (en) * 2013-03-15 2014-09-25 Ligand Pharmaceuticals Incorporated Methods of treatment associated with the granulocyte colony-stimulating factor receptor
US20190388338A1 (en) * 2016-05-06 2019-12-26 Taris Biomedical Llc Method of treating lower tract urothelial cancer
RU2675695C1 (ru) * 2018-03-06 2018-12-24 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации Способ лечения рака предстательной железы высокого и очень высокого риска

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) * 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) * 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US6316652B1 (en) * 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
AU9265698A (en) 1997-09-02 1999-03-22 Boehringer Mannheim Gmbh Mpl-receptor ligands, process for their preparation, medicaments containing themand their use for the treatment and prevention of thrombocytopaenia and anaemia
KR20020069183A (ko) * 1999-07-26 2002-08-29 시오노기세이야쿠가부시키가이샤 트롬보포이에틴 작동성을 나타내는 의약 조성물
EP1227843B1 (en) * 1999-11-10 2009-10-14 BioPheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
EP1104674A1 (de) 1999-11-10 2001-06-06 Curacyte AG O,o'-Dihydroxyazofarbstoffe als Bestandteile von Arzneimitteln mit TPO-Agonistischer oder -Synergetischer Wirkung
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
WO2001092211A1 (fr) 2000-05-30 2001-12-06 Chugai Seiyaku Kabushiki Kaisha Composes possedant des activites analogues a celles de la thrombopoietine
DE60109922D1 (de) * 2000-05-31 2005-05-12 Genzyme Corp Therapeutische verbindungen gegen eierstockkrebs
DE60203260T2 (de) * 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
JP4145655B2 (ja) 2001-01-26 2008-09-03 塩野義製薬株式会社 トロンボポエチン受容体アゴニスト作用を有するハロゲン化合物
JP4145654B2 (ja) 2001-01-26 2008-09-03 塩野義製薬株式会社 トロンボポエチン受容体アゴニスト作用を有する環状化合物
WO2002062775A1 (fr) 2001-02-02 2002-08-15 Yamanouchi Pharmaceutical Co., Ltd. Dérivé de 2-acylaminothiazole ou son sel
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
KR20040048900A (ko) * 2001-09-24 2004-06-10 토스크, 인코포레이티드 감소된 독성 시스플라틴 포뮬레이션 및 이의 이용 방법
KR101010905B1 (ko) 2002-01-18 2011-01-25 아스텔라스세이야쿠 가부시키가이샤 2-아실아미노티아졸 유도체 또는 그 염
TWI280128B (en) 2002-05-22 2007-05-01 Smithkline Beecham Corp 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
WO2004029049A1 (ja) * 2002-09-30 2004-04-08 Yamanouchi Pharmaceutical Co., Ltd. 2-アシルアミノチアゾール誘導体の新規な塩
WO2004096154A2 (en) 2003-04-29 2004-11-11 Smithkline Beecham Corporation Methods for treating degenerative diseases/injuries
WO2005118551A2 (en) 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
US7314887B2 (en) * 2004-10-25 2008-01-01 Ligand Pharmaceuticals, Inc. Thrombopoietin activity modulating compounds and methods
CA2630234A1 (en) 2005-11-23 2007-05-31 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
CN101437792A (zh) 2006-03-15 2009-05-20 利亘制药公司 血小板生成素活性调节化合物的合成

Also Published As

Publication number Publication date
AU2008216106B9 (en) 2013-09-05
CA2678358A1 (en) 2008-08-21
CN101662937A (zh) 2010-03-03
TR201809010T4 (tr) 2018-07-23
WO2008101141A2 (en) 2008-08-21
TW200906393A (en) 2009-02-16
EA017715B1 (ru) 2013-02-28
IL200319A (en) 2015-05-31
MX2009008822A (es) 2009-08-28
US20100075928A1 (en) 2010-03-25
MA31202B1 (fr) 2010-02-01
AU2008216106B2 (en) 2013-07-11
BRPI0807940B8 (pt) 2021-05-25
JP2010519221A (ja) 2010-06-03
WO2008101141A3 (en) 2008-10-16
EP2124547A4 (en) 2010-05-05
HUE038563T2 (hu) 2018-10-29
KR20090113330A (ko) 2009-10-29
US20090022814A1 (en) 2009-01-22
AU2008216106A1 (en) 2008-08-21
PE20081784A1 (es) 2009-01-25
CN101662937B (zh) 2014-03-12
SI2124547T1 (en) 2018-08-31
IL238394B (en) 2018-05-31
BRPI0807940B1 (pt) 2020-10-27
CR10997A (es) 2009-10-16
AR065348A1 (es) 2009-06-03
JP5511391B2 (ja) 2014-06-04
IL238394A0 (en) 2015-06-30
CA2678358C (en) 2015-12-08
EA200970776A1 (ru) 2010-02-26
PT2124547T (pt) 2018-07-04
NZ579068A (en) 2012-05-25
DK2124547T3 (en) 2018-07-16
IL200319A0 (en) 2010-04-29
ZA200905532B (en) 2010-04-28
KR101447763B1 (ko) 2014-10-07
PL2124547T3 (pl) 2018-08-31
EP2124547B1 (en) 2018-03-28
ES2675070T3 (es) 2018-07-06
EP2124547A2 (en) 2009-12-02
BRPI0807940A2 (pt) 2013-07-30

Similar Documents

Publication Publication Date Title
UY30915A1 (es) Método de tratamiento de canceres
CY1123404T1 (el) Αντι-girt αντισωματα
CY1124144T1 (el) Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1121065T1 (el) Αναστολεις ιβατ για την αγωγη ηπατικων νοσων
CY1119251T1 (el) Θεραπεια συνδυασμου ενος αφουκοζυλιωμενου αντισωματος cd20 με μπενδαμουστινη
CY1117859T1 (el) Αντισωματα και ανοσοσυζευγματα anti-cd79b και μεθοδοι χρησης
NZ748314A (en) Anti-cmet antibody drug conjugates and methods for their use
CY1115700T1 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79b και μεθοδοι χρησης
EA201790850A1 (ru) Конъюгаты антитело-лекарственное средство (adc), связывающиеся с белками 191p4d12
EA201170940A1 (ru) Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела
DOP2012000155A (es) Terapia combinada para el tratamiento del cancer y ensayos de diagnostico relacionados
ECSP10010446A (es) Uso de ranolazina para el tratamiento del dolor
TR201821029T4 (tr) Geliştirilmiş antı-IL-23p19 antikorları.
CL2008001626A1 (es) Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
MY176031A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
EA200701094A1 (ru) Усовершенствованное лечение рака с применением агонистов tlr3
UA103004C2 (ru) Гуманизированное антитело против cd79b и иммуноконъюгаты и способы применения
PA8849001A1 (es) Anticuerpos de c-met
PA8804901A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo
CY1119800T1 (el) Συνδυασμοι υποδοχεα της 5-ητ4 και αναστολεων ακετυλοχολινεστερασης για τη θεραπεια γνωστικων διαταραχων
MA33973B1 (fr) Méthodes de traitement du cancer à l&#39;aide d&#39;antagonistes de notch
BRPI0908635A8 (pt) composto, composição farmacêutica e método de tratamento de câncer
CY1123614T1 (el) Μεθοδος θεραπειας δυσκινησιας
EA200970885A1 (ru) Комбинирование лечения рака с применением il-18 человека и антитела против cd20
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico